Your session is about to expire
← Back to Search
TL-925 Arm for Dry Eye Syndrome
Study Summary
This trial will test a new eye drop to treat moderate-severe Dry Eye Disease in 100 people, with two phases of 2 wks screening/run-in and 4 wks double-masked treatment.
- Dry Eye Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the TL-925 Arm been given the blessing of regulatory authorities?
"As this is a Phase 2 clinical trial, we have assigned TL-925 Arm with an intermediate safety rating of 2. This reflects the presence of supporting data for its security and lack thereof regarding efficacy."
What is the cap on participants for this clinical trial?
"Affirmative. According to publicly available data on clinicaltrials.gov, this ongoing medical study was launched on February 27th 2023 and has since been amended on March 9th of the same year. The research is actively seeking out 100 participants from 3 distinct sites."
Does this experiment have any available openings for participants?
"Yes, the clinicaltrials.gov website indicates that this investigation is actively seeking out participants. This clinical trial was first published on February 27th 2023 and has been updated as recently as March 9th 2023. A total of one hundred individuals need to be recruited across three different medical centres."
Share this study with friends
Copy Link
Messenger